Metabolic dysfunction-associated fatty liver disease (MAFLD) is a new acronym adopted from the consensus of international experts. Given the increasing prevalence of MAFLD in pre-transplant settings, de novo and recurrent graft steatosis/MAFLD are common in post-transplant settings. The impact of graft steatosis on long-term outcomes is unclear. The current knowledge of incidence rate, risk factors, diagnosis, long-term outcomes, and management of graft steatosis (both de novo and recurrent) is discussed in this review.
Keywords: De novo; Fibrosis; Graft steatosis; Metabolic dysfunction-associated fatty liver disease; Metabolic dysfunction-associated steatohepatitis; Recurrent; Survival.
©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.